Medidata Solutions (NASDAQ:MDSO) had its target price boosted by Piper Jaffray Companies to $98.00 in a research report released on Wednesday morning. Piper Jaffray Companies currently has an overweight rating on the stock.
Other analysts have also recently issued research reports about the company. Royal Bank of Canada set a $82.00 price objective on Medidata Solutions and gave the stock a hold rating in a research report on Thursday, February 8th. TheStreet raised Medidata Solutions from a c+ rating to a b- rating in a research report on Monday, March 12th. Dougherty & Co restated a buy rating and issued a $89.00 target price (up previously from $79.00) on shares of Medidata Solutions in a research note on Thursday, May 10th. ValuEngine upgraded Medidata Solutions from a sell rating to a hold rating in a research note on Thursday, April 12th. Finally, BidaskClub upgraded Medidata Solutions from a hold rating to a buy rating in a research note on Friday, May 4th. Five research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. The stock has an average rating of Buy and a consensus price target of $84.50.
Medidata Solutions opened at $75.33 on Wednesday, Marketbeat Ratings reports. The company has a quick ratio of 1.63, a current ratio of 1.63 and a debt-to-equity ratio of 0.18. The firm has a market capitalization of $4.46 billion, a PE ratio of 82.78, a price-to-earnings-growth ratio of 3.78 and a beta of 1.49. Medidata Solutions has a 1-year low of $59.60 and a 1-year high of $85.92.
Medidata Solutions (NASDAQ:MDSO) last posted its quarterly earnings data on Thursday, April 19th. The company reported $0.40 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.35 by $0.05. The firm had revenue of $149.20 million during the quarter, compared to analysts’ expectations of $146.73 million. Medidata Solutions had a return on equity of 11.36% and a net margin of 7.96%. The business’s quarterly revenue was up 16.9% on a year-over-year basis. During the same quarter last year, the firm earned $0.31 EPS. equities research analysts expect that Medidata Solutions will post 0.98 EPS for the current fiscal year.
In other Medidata Solutions news, EVP Michael I. Otner sold 10,395 shares of Medidata Solutions stock in a transaction dated Wednesday, April 25th. The stock was sold at an average price of $70.05, for a total transaction of $728,169.75. Following the completion of the transaction, the executive vice president now owns 74,165 shares in the company, valued at approximately $5,195,258.25. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Rouven Bergmann sold 2,000 shares of Medidata Solutions stock in a transaction dated Monday, March 19th. The shares were sold at an average price of $66.30, for a total value of $132,600.00. Following the transaction, the chief financial officer now owns 94,744 shares of the company’s stock, valued at approximately $6,281,527.20. The disclosure for this sale can be found here. Insiders sold a total of 46,231 shares of company stock valued at $3,258,559 in the last 90 days. 4.70% of the stock is currently owned by company insiders.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Clearbridge Investments LLC raised its stake in shares of Medidata Solutions by 0.4% during the 4th quarter. Clearbridge Investments LLC now owns 2,171,755 shares of the company’s stock valued at $137,624,000 after buying an additional 9,425 shares during the last quarter. Champlain Investment Partners LLC increased its stake in shares of Medidata Solutions by 15.7% in the 1st quarter. Champlain Investment Partners LLC now owns 2,148,615 shares of the company’s stock valued at $134,955,000 after purchasing an additional 291,630 shares in the last quarter. American Century Companies Inc. increased its stake in shares of Medidata Solutions by 0.3% in the 1st quarter. American Century Companies Inc. now owns 1,444,426 shares of the company’s stock valued at $90,724,000 after purchasing an additional 4,716 shares in the last quarter. Global Thematic Partners LLC increased its stake in shares of Medidata Solutions by 37.3% in the 4th quarter. Global Thematic Partners LLC now owns 1,429,138 shares of the company’s stock valued at $90,564,000 after purchasing an additional 388,608 shares in the last quarter. Finally, Disciplined Growth Investors Inc. MN increased its stake in shares of Medidata Solutions by 12.2% in the 1st quarter. Disciplined Growth Investors Inc. MN now owns 932,254 shares of the company’s stock valued at $58,555,000 after purchasing an additional 101,398 shares in the last quarter.
Medidata Solutions Company Profile
Medidata Solutions, Inc provides cloud-based solutions for life sciences worldwide. It offers the Medidata Clinical Cloud, a platform, pioneering analytics, and clinical technology for the development of new therapies. The company's platform solutions include data capture and management and trial planning and management.
Receive News & Ratings for Medidata Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medidata Solutions and related companies with MarketBeat.com's FREE daily email newsletter.